OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Leishmania Infection during Ruxolitinib Treatment: The Cytokines-Based Immune Response in the Setting of Immunocompromised Patients
Andrea Duminuco, Salvatore Scarso, Alessandra Cupri, et al.
Journal of Clinical Medicine (2023) Vol. 12, Iss. 2, pp. 578-578
Open Access | Times Cited: 11
Andrea Duminuco, Salvatore Scarso, Alessandra Cupri, et al.
Journal of Clinical Medicine (2023) Vol. 12, Iss. 2, pp. 578-578
Open Access | Times Cited: 11
Showing 11 citing articles:
Myelofibrosis and Survival Prognostic Models: A Journey between Past and Future
Andrea Duminuco, Antonella Nardo, Gaetano Giuffrida, et al.
Journal of Clinical Medicine (2023) Vol. 12, Iss. 6, pp. 2188-2188
Open Access | Times Cited: 16
Andrea Duminuco, Antonella Nardo, Gaetano Giuffrida, et al.
Journal of Clinical Medicine (2023) Vol. 12, Iss. 6, pp. 2188-2188
Open Access | Times Cited: 16
Debulking Therapy with Obinutuzumab Is Helpful and Safe in Chronic Lymphocytic Leukemia with Extreme Hyperleukocytosis: A Case Report
Dario Leotta, Andrea Duminuco, Marina Parisi, et al.
Onco (2025) Vol. 5, Iss. 1, pp. 10-10
Open Access
Dario Leotta, Andrea Duminuco, Marina Parisi, et al.
Onco (2025) Vol. 5, Iss. 1, pp. 10-10
Open Access
A Journey Through JAK Inhibitors for the Treatment of Myeloproliferative Diseases
Andrea Duminuco, Elena Torre, Giuseppe A. Palumbo, et al.
Current Hematologic Malignancy Reports (2023) Vol. 18, Iss. 5, pp. 176-189
Closed Access | Times Cited: 14
Andrea Duminuco, Elena Torre, Giuseppe A. Palumbo, et al.
Current Hematologic Malignancy Reports (2023) Vol. 18, Iss. 5, pp. 176-189
Closed Access | Times Cited: 14
ACVR1: A Novel Therapeutic Target to Treat Anemia in Myelofibrosis
Andrea Duminuco, Helen T. Chifotides, Sebastiano Giallongo, et al.
Cancers (2023) Vol. 16, Iss. 1, pp. 154-154
Open Access | Times Cited: 12
Andrea Duminuco, Helen T. Chifotides, Sebastiano Giallongo, et al.
Cancers (2023) Vol. 16, Iss. 1, pp. 154-154
Open Access | Times Cited: 12
Emergencies in Hematology: Why, When and How I Treat?
Andrea Duminuco, Vittorio Del Fabro, Luca Patanè, et al.
Journal of Clinical Medicine (2024) Vol. 13, Iss. 24, pp. 7572-7572
Open Access | Times Cited: 3
Andrea Duminuco, Vittorio Del Fabro, Luca Patanè, et al.
Journal of Clinical Medicine (2024) Vol. 13, Iss. 24, pp. 7572-7572
Open Access | Times Cited: 3
Polycythemia Vera: Barriers to and Strategies for Optimal Management
Andrea Duminuco, Patrick Harrington, Claire Harrison, et al.
Blood and Lymphatic Cancer Targets and Therapy (2023) Vol. Volume 13, pp. 77-90
Open Access | Times Cited: 8
Andrea Duminuco, Patrick Harrington, Claire Harrison, et al.
Blood and Lymphatic Cancer Targets and Therapy (2023) Vol. Volume 13, pp. 77-90
Open Access | Times Cited: 8
The pharmacotherapeutic management of patients with myelofibrosis: looking beyond JAK inhibitors
Andrea Duminuco, Calogero Vetro, Cesarina Giallongo, et al.
Expert Opinion on Pharmacotherapy (2023) Vol. 24, Iss. 13, pp. 1449-1461
Closed Access | Times Cited: 7
Andrea Duminuco, Calogero Vetro, Cesarina Giallongo, et al.
Expert Opinion on Pharmacotherapy (2023) Vol. 24, Iss. 13, pp. 1449-1461
Closed Access | Times Cited: 7
Andrea Duminuco, Adrián Mosquera Orgueira, Antonella Nardo, et al.
Cancer Reports (2023) Vol. 6, Iss. 10
Open Access | Times Cited: 4
Exploring emerging JAK inhibitors in the treatment of aicardi-goutières syndrome
Davide Politano, Davide Tonduti, Roberta Battini, et al.
Expert Opinion on Emerging Drugs (2024)
Closed Access
Davide Politano, Davide Tonduti, Roberta Battini, et al.
Expert Opinion on Emerging Drugs (2024)
Closed Access
Occurrence of lymphoproliferative disorders during ruxolitinib treatment: May fedratinib be the turning point?
Andrea Duminuco, Antonella Nardo, Giuseppe A. Palumbo
Hematological Oncology (2024) Vol. 42, Iss. 2
Closed Access
Andrea Duminuco, Antonella Nardo, Giuseppe A. Palumbo
Hematological Oncology (2024) Vol. 42, Iss. 2
Closed Access
